Vivoryon Therapeutics
GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from
VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to
Improve Kidney Function
Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024
Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s abstract “Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD)” has been selected for a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, California, held October 23 to 27.
Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual Kidney Disease Key Opinion Leader (KOL) Event held September 30, 2024. The event focused on the standard of care and existing medical need, market development and dynamics in kidney disorders, as well as on key statistical considerations in kidney disease drug development, with special emphasis on diabetic kidney disease (DKD).
Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association
Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024
P R O D U C T S U G G E S T I O N S
